Revelation Biosciences IncRevelation Biosciences Inc
Revelation Biosciences Inc

Revelation Biosciences Inc

REVB
Health Care·Biotechnology

Revelation Biosciences, Inc. engages in the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.

California; U.S.A
Market cap
$3.1MNo data
Revenue
No dataNo data
Net income
$-8.9M+40.7% YoY
Free cash flow
$-8.3M+54.8% YoY

Market

Listed stock
REVBPriceNasdaq
Loading…Loading…1Y

Financial performance

Revenue
No dataNo data
Operating income
$-9.1M−13.7% YoY
Net income
$-8.9M+40.7% YoY
Free cash flow
$-8.3M+54.8% YoY

Revenue, profit & cash trend

Revenue
Reference
Revenue: 2021 $0, 2022 $0, 2023 $0, 2024 $0. Reference line: Reference at $0.

Growth & profitability

Revenue growth
No dataNo data
Gross margin
No dataNo data
Operating margin
No dataNo data
FCF margin
No dataNo data

Earnings power over time

Operating income
Net income
Free cash flow
Operating income: 2021-12-31 $-12M, 2022-12-31 $-10.9M, 2023-12-31 $-8.7M, 2024-12-31 $-8M, 2025-12-31 $-9.1M. Net income: 2021-12-31 $-12M, 2022-12-31 $-10.8M, 2023-12-31 $-120.3K, 2024-12-31 $-15M, 2025-12-31 $-8.9M. Free cash flow: 2021-12-31 $-725.6K, 2022-12-31 $-11.4M, 2023-12-31 $-7.3M, 2024-12-31 $-18.3M, 2025-12-31 $-8.3M

Growth heatmap

202220232024CAGR
Revenue
No data
No data
No data
No data
Gross profit
No data
No data
No data
No data
No data
Operating income
+9.1%
+20.3%
+7.9%
-13.7%
No data
Free cash flow
-1464.4%
+35.8%
-151.7%
+54.8%
No data

Earnings quality

Operating cash flow
$-8.3M+54.9% YoY
Net income
$-8.9M+40.7% YoY
Free cash flow
$-8.3M+54.8% YoY
Diluted EPS
No dataNo data

Cash conversion quality

Operating cash flow
Free cash flow
Net income = 100%
Operating cash flow: 2025-12-31 93%, 2024-12-31 122%, 2023-12-31 6059%, 2022-12-31 104%, 2021-12-31 6%. Free cash flow: 2025-12-31 93%, 2024-12-31 122%, 2023-12-31 6059%, 2022-12-31 105%, 2021-12-31 6%. Reference line: Net income = 100% at 100%.

Per-share economics

Diluted EPS
Latest
No data
FCF / share
Latest
No data
Diluted shares
Latest
No data

Financial flexibility

Cash & equivalents
No dataNo data
Total debt
No dataNo data
Net debt
No dataNo data
Current ratio
No dataNo data

Cash Coverage of Debt

Cash / Total debt
No data

Returns

Return on equity
No dataNo data
Return on assets
No dataNo data
Return on invested capital
No dataNo data
Asset turnover
No dataNo data

Return on capital

No data

Valuation

Price to earnings
No dataNo data
Price to sales
No dataNo data
EV / EBITDA
No dataNo data
Free cash flow yield
No dataNo data

Valuation vs its own 5Y history

Metric
Own five-year range
Current
Own 5Y median
Position in own range
Price to earnings
No data
No data
No data
No data
Price to sales
No data
No data
No data
No data
EV / EBITDA
No data
No data
No data
No data
Free cash flow yield
No data
No data
No data
No data